Limitations, agreements, and source contact

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

ClinicalTrials.gov@lilly.com

organization

Eli Lilly and Company

phone

800- 545-5979

title

Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice